Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of fenfluramine in myoclonic astatic epilepsy (Doose syndrome)
2024-518520-77-00Phase 2Authorised
- Sponsor
- Universitätsklinikum Schleswig-Holstein
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fenfluramine in myoclonic astatic epilepsy (MAE), sponsored by Universitätsklinikum Schleswig-Holstein. Primary endpoints: Change in seizure number and frequency, Serious adverse events and 7 more. Planned start Oct 2024; status: authorised.
02
Drugs
fenfluramine
03
Conditions
myoclonic astatic epilepsy (MAE)
Beyond the preview
Go deeper on 2024-518520-77-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518520-77-00.